CN104666267A - 一种阿昔洛韦药物组合物 - Google Patents
一种阿昔洛韦药物组合物 Download PDFInfo
- Publication number
- CN104666267A CN104666267A CN201510040993.XA CN201510040993A CN104666267A CN 104666267 A CN104666267 A CN 104666267A CN 201510040993 A CN201510040993 A CN 201510040993A CN 104666267 A CN104666267 A CN 104666267A
- Authority
- CN
- China
- Prior art keywords
- acyclovir
- pharmaceutical composition
- release
- composition according
- select
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229960004150 aciclovir Drugs 0.000 title claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 9
- 239000003792 electrolyte Substances 0.000 claims abstract description 9
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000007779 soft material Substances 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 8
- -1 polypropylene Polymers 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 239000002075 main ingredient Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000013268 sustained release Methods 0.000 abstract description 4
- 239000012730 sustained-release form Substances 0.000 abstract description 4
- 239000007939 sustained release tablet Substances 0.000 abstract description 3
- 238000005550 wet granulation Methods 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000003405 delayed action preparation Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510040993.XA CN104666267B (zh) | 2015-03-27 | 2015-03-27 | 一种阿昔洛韦药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510040993.XA CN104666267B (zh) | 2015-03-27 | 2015-03-27 | 一种阿昔洛韦药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104666267A true CN104666267A (zh) | 2015-06-03 |
CN104666267B CN104666267B (zh) | 2017-08-08 |
Family
ID=53302214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510040993.XA Active CN104666267B (zh) | 2015-03-27 | 2015-03-27 | 一种阿昔洛韦药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104666267B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212957A (zh) * | 2005-06-29 | 2008-07-02 | 万能药生物有限公司 | 药物缓释组合物及其制备方法 |
CN101502521A (zh) * | 2008-09-04 | 2009-08-12 | 山东淄博新达制药有限公司 | 阿昔洛韦缓释制剂组合物及其制备方法 |
WO2009153632A1 (en) * | 2008-06-19 | 2009-12-23 | University Of Witwatersrand, Johannesburg | A gastroretentive pharmaceutical dosage form |
CN101647786A (zh) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | 阿昔洛韦缓释片及其制备方法 |
-
2015
- 2015-03-27 CN CN201510040993.XA patent/CN104666267B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212957A (zh) * | 2005-06-29 | 2008-07-02 | 万能药生物有限公司 | 药物缓释组合物及其制备方法 |
WO2009153632A1 (en) * | 2008-06-19 | 2009-12-23 | University Of Witwatersrand, Johannesburg | A gastroretentive pharmaceutical dosage form |
CN101647786A (zh) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | 阿昔洛韦缓释片及其制备方法 |
CN101502521A (zh) * | 2008-09-04 | 2009-08-12 | 山东淄博新达制药有限公司 | 阿昔洛韦缓释制剂组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
吕竹芬等: "阿昔洛韦缓释片的制备及体外释药的研究", 《广东药学院学报》 * |
吴宁萍等: "阿昔洛韦缓释片的工艺研究", 《中国现代应用药学杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN104666267B (zh) | 2017-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101562608B1 (ko) | 호흡기 질환에 작용하는 복합 화학 약물, 그들의 제조 방법 및 용도 | |
CN102077955B (zh) | 可溶性魔芋膳食纤维片及其制作方法 | |
CN103083560A (zh) | 天麻酸枣仁复合胶囊 | |
CN105030793A (zh) | 二甲双胍格列本脲胶囊及其制备方法 | |
CN104666267A (zh) | 一种阿昔洛韦药物组合物 | |
CN102319225B (zh) | 一种盐酸曲美他嗪缓释片及其制备方法 | |
CN102119931A (zh) | 一种新的盐酸二甲双胍缓释片及其制备方法 | |
CN111110696A (zh) | 一种组合物、制剂及用途 | |
CN111419811A (zh) | 一种富马酸替诺福韦艾拉酚胺组合物 | |
CN102144984A (zh) | 一种易于溶出的拉米夫定片及其制备方法 | |
CN102552211B (zh) | 一种阿戈美拉汀的制剂组合物及其制备方法 | |
CN101732555A (zh) | 一种治疗感冒咳嗽及慢性支气管炎的药 | |
CN101732302A (zh) | 绿原酸在制备治疗肺纤维化的药中的应用 | |
CN1526390A (zh) | 一种匹多莫德的颗粒剂及其制备方法 | |
CN100471497C (zh) | 盐酸纳洛酮鼻粉剂 | |
CN113975259A (zh) | 一种盐酸氨溴索复方泡腾片及其制备方法 | |
CN104248626B (zh) | 左乙拉西坦泡腾干混悬剂及其制备方法 | |
CN101647786B (zh) | 阿昔洛韦缓释片及其制备方法 | |
CN109513008B (zh) | 一种治疗特发性间质性肺炎的药物组合物及其制备方法 | |
CN105343026B (zh) | 草酸艾司西酞普兰泡腾片配方与制备工艺 | |
CN100435804C (zh) | 司他夫定口服速释制剂及制备方法 | |
JP2015107951A (ja) | 顆粒剤 | |
CN1778297A (zh) | 一种酚妥拉明泡腾片及其制备方法 | |
CN102784116A (zh) | 一种高溶出度非诺贝特分散片及其制备方法 | |
CN103251566A (zh) | 片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acyclovir pharmaceutical composition Effective date of registration: 20210730 Granted publication date: 20170808 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20170808 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: No.8 Kangpu Avenue, high tech Industrial Park, Hanshou County, Changde City, Hunan Province, 415900 Patentee after: KAMP PHARMACEUTICALS Co.,Ltd. Address before: 12 / F, building B, Lugu information port, 658 Lugu Avenue, high tech Zone, Changsha City, Hunan Province, 410205 Patentee before: KAMP PHARMACEUTICALS Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acyclovir pharmaceutical composition Effective date of registration: 20211028 Granted publication date: 20170808 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |